Bictegravir is a new integrase strand transfer inhibitor (INSTI) with a high genetic barrier to
the development of HIV-1 resistance. The drug is co-formulated with the nucleos (t) ide …

Abstract Purpose of Review Cabotegravir is a potent integrase strand transfer inhibitor
(INSTI) recently approved as a long-acting injectable formulation for HIV prevention (CAB …

Background Integrase strand transfer inhibitors (INSTIs) are recommended for first-line HIV
therapy based on their relatively high genetic barrier to resistance. Although raltegravir …

Background Integrase strand transfer inhibitors (INSTIs) are the class of antiretroviral (ARV)
drugs most recently approved by the FDA for the treatment of HIV-1 infections. INSTIs block …

A once every eight-week cabotegravir (CAB) long-acting parenteral is more effective than
daily oral emtricitabine and tenofovir disoproxil fumarate in preventing human …

Ongoing with current combinations of antiretroviral drugs for the treatment of Human
Immunodeficiency Virus (HIV) infection can successfully maintain long-term suppression of …

The HIV integrase (IN) strand transfer inhibitor (INSTI) bictegravir (BIC) has a long
dissociation half-life (t 1/2) from wild-type IN-DNA complexes: BIC 163 h> dolutegravir (DTG) …

Available antiretroviral drugs have demonstrated effectiveness in both pre-exposure
prophylaxis and treatment of HIV infection. However, some concerns still persist regarding …

The increasing use of the integrase strand transfer inhibitor (INSTI) class for the treatment of
HIV-infection has pointed to the importance of analyzing the features of HIV-1 subtypes for …

Baseline plasma samples of 490 randomly selected antiretroviral therapy (ART) naïve
patients from seven hospitals participating in the first nationwide Ethiopian HIV-1 cohort …